Japan Preimplantation Genetic Testing Market Size, Share, and COVID-19 Impact Analysis, By Product (Reagents & Consumables, Instruments, and Software), By Procedure (Preimplantation Genetic Screening and Preimplantation Genetic Diagnosis), By Application (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, and Other Applications), and Japan Preimplantation Genetic Testing Market Insights, Industry Trend, Forecasts to 2035

Japan Preimplantation Genetic Testing Market Insights Forecasts to 2035

• The Japan Preimplantation Genetic Testing Market Size Was Estimated at USD 66.7 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.2% from 2025 to 2035
• The Japan Preimplantation Genetic Testing Market Size is Expected to Reach USD 116.5 Million by 2035

According to a research report published by Spherical Insights & Consulting, The Japan Preimplantation Genetic Testing Market Size is anticipated to reach USD 116.5 Million by 2035, growing at a CAGR of 5.2% from 2025 to 2035. The Japan preimplantation genetic testing (PGT) market is growing due to the increasing genetic disorders, growing infertility, sophisticated screening technology, and improved knowledge of hereditary diseases. Delayed childbearing additionally fuels demand, making PGT a key part of assisted reproductive technologies (ART).

Market Overview

The Japan preimplantation genetic testing (PGT) market, also referred to as preimplantation genetic screening or diagnosis, is the diagnosis of embryos produced through IVF for the identification of genetic disorders, aneuploidies, monogenic diseases, and chromosomal structural abnormalities before implantation. In Japan, its primary applications are reducing the risk of miscarriage, especially in women of advanced maternal age, and preventing the transmission of severe inherited conditions like Duchenne muscular dystrophy or chromosomal rearrangements. Key strengths of the Japanese market are a robust healthcare infrastructure, accredited genetic test labs, telemedicine for wider access, and expanding incorporation of pharmacogenomics and predictive medicine. Prospects exist to extend eligibility on the basis of the 2021 to 2022 guideline updates, broader public awareness, urban rural extension, and exploiting NGS technologies. Main driving forces in the market are growing awareness of genetic welfare and infertility treatments, growing adoption of IVF, and innovations in next generation sequencing and microarray technologies, improving precision and reducing expenses. Professional organizations and governments, such as the Japan Society of Obstetrics and Gynecology (JSOG) and the Japanese Association of Medical Sciences, are revising ethical guidelines, authorizing more extensive applications of PGT while maintaining rigorous case review and genetic counselling procedures.

Report Coverage

This research report categorizes the market for the Japan preimplantation genetic testing market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan preimplantation genetic testing market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan preimplantation genetic testing market.

Driving Factors

The Japan preimplantation genetic testing (PGT) market is fueled by increasing rates of infertility, late childbearing, and increased awareness of genetic disease. Growing utilization of in vitro fertilization (IVF) treatment, combined with advances in genetic screening technologies such as next-generation sequencing, increases test accuracy and affordability. Government policies, revision of ethical guidelines, and regulatory approval of more extensive clinical applications have further stimulated demand. Also, the increasing aging population and increased risks of miscarriage have created demand for PGT to ensure safer pregnancies.

Restraining Factors

The Japan preimplantation genetic testing market is threatened by stringent ethical regulations, low public awareness, and high procedure costs. Also, limited insurance reimbursement and separate approval complexities restrict wider adoption and access.

Market Segmentation

The Japan preimplantation genetic testing market share is classified into product, procedure, and application.

• The reagents & consumables segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan preimplantation genetic testing market is segmented by product into reagents & consumables, instruments, and software.  Among these, the reagents & consumables segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to preimplantation genetic diagnosis (PGD) is used to test embryos for inherited disorders before implantation, often performed by couples at risk of transmitting conditions such as cystic fibrosis or Huntington's disease. Increased rates of genetic disorders, coupled with the further development of technologies such as NGS and PCR, have brought PGD into the spotlight in reproductive medicine.

• The preimplantation genetic diagnosis segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan preimplantation genetic testing market is segmented by procedure into preimplantation genetic screening and preimplantation genetic diagnosis. Among these, the preimplantation genetic diagnosis segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. PGT demands constant application of materials such as DNA extraction kits, PCR and sequencing reagents, probes, and microarrays. Their high consumption rate and repetitive need make them non-negotiable for fertility clinics and laboratories. Increasing dependency on NGS and PCR technologies also fuels demand for accurate, high-quality screening reagents.

• The aneuploidy screening segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan preimplantation genetic testing market is segmented by application into chromosomal abnormalities, X linked diseases, embryo testing, aneuploidy screening, HLA typing, and other applications. Among these, the aneuploidy screening segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is attributed to the high incidence of chromosomal abnormalities of embryos, i.e., aneuploidy, which necessitates the demand for genetic screening to improve IVF success. Down, Turner, and Edwards syndromes are usually caused by these abnormalities. As many as 50 percent of IVF embryos may be affected, and therefore, whole aneuploidy screening becomes increasingly necessary.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan preimplantation genetic testing market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Illumina Inc.
• Invitae Corporation
• Takara Bio
• Sysmex Corporation
• The Cooper Companies, Inc.
• Thermo Fisher Scientific Inc.
• Revvity
• Agilent Technologies Inc.
• Genea Limited
• BGI / Yikon Genomics
• Macrogen Japan
• Natera Inc.
• Labcorp Holdings Inc.
• Others

Recent Developments:

• In March 2024, Sysmex Corporation launched six new hormone assay kits for its HISCL Series systems in Japan, improving gynecological and gonadal diagnostics. These kits enable rapid, simple blood hormone testing, supporting diagnosis and treatment of gynecological disorders and infertility, and align with Sysmex’s strategy to expand its immunochemistry business.

• In May 2025, Illumina received approval from the Japan MHLW for its TruSight Oncology Comprehensive test, a Class III or IV medical device. This genomic test analyzes DNA or RNA variants across 500+ genes, aiding oncologists in selecting targeted therapies and clinical trials, thus improving precision oncology and accelerating personalized medicine in Japan.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan preimplantation genetic testing market based on the below-mentioned segments:

Japan Preimplantation Genetic Testing Market, By Product

• Reagents & Consumables
• Instruments
• Software

Japan Preimplantation Genetic Testing Market, By Procedure

• Preimplantation Genetic Screening
• Preimplantation Genetic Diagnosis

Japan Preimplantation Genetic Testing Market, By Application

• Chromosomal Abnormalities
• X-linked Diseases
• Embryo Testing
• Aneuploidy Screening
• HLA Typing
• Other Applications